Lumida
/KIDS
⌘K
OrthoPediatrics Corp

OrthoPediatrics Corp

KIDS
$22.06USD+2.32%+0.50 today

MARKET CAP

576.0M

P/E (TTM)

FWD P/E

DAY RANGE

$21 – $22

52W RANGE

$14
$27

AI Summary

Stalk
Sell NowHigh

KIDS remains in a Stage 4 decline with confirmed lower highs and lows and price below all key moving averages; there are no signs of selling exhaustion, volume and volatility support further downside, and both medium- and short-term signals align with a bearish continuation, favoring selling on breakdown into the next support area.

  • Q2 2026 revenue grew 15% YoY to $70.5M, led by trauma and deformity products.
  • Launched 3P Pediatric Plating Platform Hip System; management expects revenue to build further.
  • Net losses persist; weak profitability metrics raise questions on long-term returns.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$98.0M$122.3M$148.7M$204.7M$236.3M
YoY %+37.9%+24.7%+21.6%+37.6%+15.4%
P / Sales11.8x7.0x5.0x2.6x1.8x
EV / Sales12.5x7.3x5.2x3.0x2.4x
Gross Profit, Adj.$73.4M$90.7M$111.3M$148.6M$172.7M
YoY %+33.4%+23.5%+22.7%+33.6%+16.2%
Margin %74.9%74.1%74.8%72.6%73.1%
EV / Gross Profit16.7x9.9x7.0x4.1x3.2x
EBITDA, Adj.$-7.2M$-8.7M$-8.4M$-10.4M$-7.9M
YoY %+42.0%-20.8%+3.6%-24.6%+24.5%
Margin %-7.3%-7.1%-5.6%-5.1%-3.3%
EV / EBITDA-170.2x-103.4x-93.0x-58.4x-71.0x
EBIT$-16.2M$531,000$-26.8M$-35.0M$-39.2M
YoY %+46.4%+103.3%-5137.9%-30.9%-12.1%
Margin %-16.5%0.4%-18.0%-17.1%-16.6%
EV / EBIT-75.5x1691.7x-29.1x-17.4x-14.2x
Net Income$-16.3M$1.3M$-21.0M$-37.8M$-39.6M
YoY %+50.6%+107.7%-1767.2%-80.3%-4.8%
Net Margin-16.6%1.0%-14.1%-18.5%-16.8%
EPS (GAAP)-$0.84$0.06-$0.92-$1.64-$1.69
YoY %+53.8%+107.1%-1633.3%-78.3%-3.0%